Standout Papers

Serum Prostate Specific Antigen Complexed to<i>α</i>1-Antichymotrypsin as an Indicator of Pro... 1993 2026 2004 2015 671
  1. Serum Prostate Specific Antigen Complexed toα1-Antichymotrypsin as an Indicator of Prostate Cancer (1993)
    Anders Christensson, Thomas Björk et al. The Journal of Urology
  2. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types (2002)
    José Baselga, Danny Rischin et al. Journal of Clinical Oncology

Citation Impact

1 by Nobel laureates 24 from Science/Nature 122 standout
Sub-graph 1 of 17

Citing Papers

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
30 intermediate papers

Works of Thomas Björk being referenced

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
2003
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
2002 Standout
and 1 more

Author Peers

Author PRM Rheumatology Surgery Oncology Molecular Biology Last Decade Papers Cites
Thomas Björk 2016 389 311 778 440 35 2.7k
Yury D. Tretyakov 1 11 1 20 15 492
Nicole Fowler‐Jaeger 159 2 44 12 387 8 486
Gagik Ghazaryan 2 13 73 14 536
Florian C. Uecker 13 1 59 9 5 36 325
Louisa Salmon 24 2 34 1 10 863

All Works

Loading papers...

Rankless by CCL
2026